Market Overview

Deutsche Bank Sees Decline in Onyx Pharma Shares as Overdone

Related ONXX
How to Prepare for the New Year
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen
Related AMGN
Portfolio Manager Says Now Is A Great Time To Buy Biotech
A Big Biotech ETF Is About To Get Cheaper
Cabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018 (Seeking Alpha)

Deutsche Bank's Robyn Karnauskas issued a research note Thursday morning suggesting the recent weakness in shares of Onyx Pharma (NASDAQ: ONXX) is overdone.

Onyx shares are down nearly 7 percent Thursday afternoon and have not closed in positive territory since August 1st. Over the course of August, the stock is down more than 11 percent.

Traders in the name have been responding to market chatter bidders which may or may not have been genuinely interested in Onyx are dropping out. Speculation Thursday suggests talks between Amgen (NASDAQ: AMGN) and Onyx have stalled amid a dispute over access to trial data.

Karnauskas called a deal between Amgen and Onyx still likely. He pointed out there have always been possible issues related to Onyx's Focus trial, with the margin of success generally being characterized as "narrow."

Deutsche Bank maintains a Hold rating and $140 price target on shares of Onyx.

Latest Ratings for ONXX

Nov 2013Stifel NicolausTerminates
Aug 2013Maxim GroupDowngradesBuyHold
Aug 2013Summer StreetDowngradesBuyNeutral

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: Analyst Color News Rumors M&A Analyst Ratings


Related Articles (AMGN + ONXX)

View Comments and Join the Discussion!

Partner Center